ClinicalTrials.gg
CompletedNCT00712465Updated Dec 3, 2010

An Interaction Study With Digoxin and AZD1305

A Phase 1 interventional study of AZD1305 and Digoxin in Atrial Fibrillation, sponsored by AstraZeneca. Completed at 1 site in Sweden. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-12-03.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Atrial Fibrillation by AstraZeneca — none open to participants now, none under way, none of them phase 3. Atrial Fibrillation · AstraZeneca.

Enrollment
11th of 11
18 · median 220
Started
2008
with 2 others
Phase 1
Only one
of the 11
Registered
7th of 11
by date

Among the 11 studies in Atrial Fibrillation by AstraZeneca, this one is the 11th largest by enrollment, is one of 3 that started in 2008, is the only one in phase 1, and was the 7th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

None of the 11 studies in Atrial Fibrillation by AstraZeneca is open now. The open studies under Atrial Fibrillation, anywhere →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 20 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Atrial Fibrillation by AstraZeneca as a file.
02

Study summary

The primary purpose of this study is to learn more about how digoxin is handled by the body, i.e. absorption, distribution, metabolism and excretion, when administered alone and in combination with AZD1305. Secondary purposes are to learn more about how AZD1305 is handled by the body when administered alone and in combination with digoxin and to learn more about how AZD1305 and digoxin administered alone and in combination affect the body.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Atrial fibrillation
  • interaction
  • pharmacokinetic
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A (BMI=weight/height2) of 19 to 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Potassium outside normal reference values
  • findings outside normal range
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    1

    AZD1305 tablet

    Drug: AZD1305

  • Experimental
    2

    AZD1305 tablet + digoxin

    Drug: AZD1305 · Drug: Digoxin

  • Active comparator
    3

    Digoxin

    Drug: Digoxin

Interventions

  • Extended Release tablet, repeated administration

  • Tablet, repeated administration

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic variables

    Time frame: During all dosing visits

Secondary outcomes

  1. Adverse event, vital signs, ECG, physical examination and laboratory variables.

    Time frame: During the study

07

Study locations

1 site
  • Research Site
    Göteborg, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2008
First posted
Jul 10, 2008
Start
Aug 2008
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Last update
Dec 3, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00712465
Lead sponsor
AstraZeneca
First posted
Jul 10, 2008
Start date
Aug 2008
Primary completion
Nov 2008
Completion
Nov 2008
Last update
Dec 3, 2010

Study contacts

Helen Lunde, MD
study director · AstraZeneca R&D, Mölndal, Sweden
Marianne Hartford, MD, PhD
principal investigator · AstraZeneca, Clinical Pharmacology Unit, Sahlgrenska University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azd-1305 · Digoxin

Start the discussion